The UK’s Centre for Medicinal Cannabis released its latest report Thursday. Titled “CBD in the UK: Towards a responsible innovative, and high-quality cannabidiol industry,”
the report provides wide-ranging recommendations including amending existing out-of-date legislation; clarity relating to current policy; investment in medical research; and self-regulation among existing business owners.
The CMC report was released at the CMC’s inaugural full day event attended by leading public health officials, academics, company medical and science officers and researchers. It fell on the final day of the inaugural European Cannabis Week, which included Cannabis Europa, a two day business summit at the Southbank Center, the IC3 Institutional Cannabis Investor’s summit, and the inaugural meeting of the Medical Cannabis Clinician’s Society (founded by Dr. Mike Barnes, who obtained the first medical cannabis licenses in the UK for Sophia Gibson and Alfie Dingley).
In addition to a call for regulation, the CMC report provides insight into the state of CBD in the UK. Among the findings:
• Approximately 6 million people have tried CBD in the UK.
• 11% of the population had consumed a CBD product in the last year.
• Use is higher in certain parts of the UK, namely Wales and Northern Ireland
• Two most important factors in choosing a product were (i) knowing the CBD product was made by a supplier that met standards, and (ii) knowing that contents were not contaminated with pesticides or heavy metals.
According to the CMC, “The political interest in cannabis policy is growing as more and more countries choose to legalize and regulate the drug for medicinal purposes,” and the UK’s recent reforms “are part of a global shift in favor of medicinal cannabis regulation across the world.”
The UK Centre For Medicinal Cannabis